trial
as of 2026-07-01Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
NCTId NCT06319170
at a glance
Phase 1 · Completed
Enrollment 106 (actual)
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc.
Primary completion 2025-01-15
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
106 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-03-28
Primary completion
2025-01-15
Eligibility
ALL · 18 Years · 64 Years
Interventions & indications
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.Lead Sponsor
Investigators
1
Teva Medical Expert, MDStudy Director
Sites
5 total
Los Alamitos, United StatesHollywood, United StatesAtlanta, United StatesDecatur, United StatesMarlton, United States
Facts & assertions
4 sourced
Enrollment
106
Phase
PHASE1
Primary Completion Date
2025-01-15
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
indication
indication
indication
investigator
person